Impairment of pre-mRNA splicing in liver disease: Mechanisms and consequences

World Journal of Gastroenterology

Volumn 16, Issue 25, 2010, Pages 3091-3102

  Berasain, Carmen ^a   Goñi, Saioa ^a   Castillo, Josefa ^a   Latasa, María Ujue ^a   Prieto, Jesús ^a   Ávila, Matías A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cell signalling; Hepatocarcinogenesis; Premrna splicing; Splicing factors; Targeted anticancer therapy

Indexed keywords

5' METHYLTHIOADENOSINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; AURORA B KINASE; CADHERIN; CADHERIN 17; DIOSPYRIN; DNA METHYLTRANSFERASE 3B; DNA TOPOISOMERASE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBRONECTIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; KRUPPEL LIKE FACTOR 6; LOCKED NUCLEIC ACID; MESSENGER RNA; PEPTIDE NUCLEIC ACID; PHOSPHOROAMIDATE MORPHOLINO OLIGONUCLEOTIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL X; PROTEIN P73; S ADENOSYLMETHIONINE; SMALL INTERFERING RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; TENSIN; TENSIN 2; TG 003; TUMOR NECROSIS FACTOR RECEPTOR 2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ANTISENSE THERAPY; AURKB SV2 GENE; CADHERIN 17 GENE; CANCER GENE THERAPY; DNMT 3 B4 GENE; DRUG MECHANISM; DRUG TARGETING; EXON; GENE; GENE EXPRESSION; HUG1 1 GENE; HUMAN; INTRON; KLF 6 GENE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MITOTIC ARREST DEFICIENT 1 GENE; NONHUMAN; P 73 GENE; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; RNA INTERFERENCE; SPLICING DEFECT; SPLICING VARIANT INVOLVED IN HEPATOCARCINOGENESIS GENE; STRUCTURE ACTIVITY RELATION; TENSIN 2VAR3 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; CARCINOMA, HEPATOCELLULAR; GENE THERAPY; GENETICS; LIVER NEOPLASMS; METABOLISM; RNA SPLICING;

CARCINOMA, HEPATOCELLULAR; EXONS; GENETIC THERAPY; HUMANS; INTRONS; LIVER NEOPLASMS; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER;

EID: 77954351642     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i25.3091     Document Type: Review

References (107)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687
3. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3: 573-588
4. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142
5. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063
6. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goñi S, Santamaría M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009; 234: 713-725
7. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49
8. Zucman-Rossi J, Laurent-Puig P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 2007; 8: 997-1003
9. Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 2009; 234: 726-736
10. Acevedo LG, Bieda M, Green R, Farnham PJ. Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors. Cancer Res 2008; 68: 2641-2651
11. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009; 69: 4059-4066
12. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-7392
13. Wörns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27: 175-188
14. Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009; 6: 423-432
15. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-328
16. Zhou W, Calciano MA, Jordan H, Brenner M, Johnson S, Wu D, Lei L, Pallares D, Beurdeley P, Rouet F, Gill PS, Bracco L, Soucaille C, Einstein R. High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity. BMC Genet 2009; 10: 63
17. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476
18. Kim E, Goren A, Ast G. Alternative splicing: current perspectives. Bioessays 2008; 30: 38-47
19. Licatalosi DD, Darnell RB. RNA processing and its regulation: global insights into biological networks. Nat Rev Genet 2010; 11: 75-87
20. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007; 8: 749-761
21. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006; 119: 2635-2641
22. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008; 24: 7-10
23. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093
24. Pettigrew CA, Brown MA. Pre-mRNA splicing aberrations and cancer. Front Biosci 2008; 13: 1090-1105
25. Körner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol 2009; 175: 461-472
26. Jensen CJ, Oldfield BJ, Rubio JP. Splicing, cis genetic variation and disease. Biochem Soc Trans 2009; 37: 1311-1315
27. Graveley BR. Sorting out the complexity of SR protein functions. RNA 2000; 6: 1197-1211
28. Shin C, Manley JL. Cell signalling and the control of premRNA splicing. Nat Rev Mol Cell Biol 2004; 5: 727-738
29. Blaustein M, Pelisch F, Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol 2007; 39: 2031-2048
30. Stamm S. Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 2008; 283: 1223-1227
31. Shomron N, Alberstein M, Reznik M, Ast G. Stress alters the subcellular distribution of hSlu7 and thus modulates alternative splicing. J Cell Sci 2005; 118: 1151-1159
32. Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadrana L, Sanford JR, Muschietti JP, Kornblihtt AR, Cáceres JF, Coso OA, Srebrow A. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 2005; 12: 1037-1044
33. Izquierdo JM, Valcárcel J. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J Biol Chem 2007; 282: 1539-1543
34. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K, Chappell DS, Birnbaum MJ, Cheng JQ, Cooper DR. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 2005; 280: 14302-14309
35. Cheng C, Yaffe MB, Sharp PA. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 2006; 20: 1715-1720
36. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008; 134: 1521-1531
37. Castillo J, Goñi S, Latasa MU, Perugorría MJ, Calvo A, Muntané J, Bioulac-Sage P, Balabaud C, Prieto J, Avila MA, Berasain C. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 2009; 137: 1805-1815.e1-4
38. Pelisch F, Blaustein M, Kornblihtt AR, Srebrow A. Crosstalk between signaling pathways regulates alternative splicing: a novel role for JNK. J Biol Chem 2005; 280: 25461-25469
39. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta 2009; 1792: 14-26
40. Li HR, Wang-Rodriguez J, Nair TM, Yeakley JM, Kwon YS, Bibikova M, Zheng C, Zhou L, Zhang K, Downs T, Fu XD, Fan JB. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens. Cancer Res 2006; 66: 4079-4088
41. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193
42. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368
43. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci USA 2002; 99: 10060-10065
44. Kanai Y, Saito Y, Ushijima S, Hirohashi S. Alterations in gene expression associated with the overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, during human hepatocarcinogenesis. J Cancer Res Clin Oncol 2004; 130: 636-644
45. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95: 611-619
46. Yasen M, Mizushima H, Mogushi K, Obulhasim G, Miyaguchi K, Inoue K, Nakahara I, Ohta T, Aihara A, Tanaka S, Arii S, Tanaka H. Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 2009; 100: 472-480
47. Schlott T, Scharf JG, Gorzel C, Middel P, Spring H. Cirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators. Br J Cancer 2002; 86: 1290-1296
48. Yam JW, Ko FC, Chan CY, Yau TO, Tung EK, Leung TH, Jin DY, Ng IO. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 2006; 44: 881-890
49. Lu X, Feng X, Man X, Yang G, Tang L, Du D, Zhang F, Yuan H, Huang Q, Zhang Z, Liu Y, Strand D, Chen Z. Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression. Clin Cancer Res 2009; 15: 3287-3296
50. Sze KM, Ching YP, Jin DY, Ng IO. Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer. Cancer Res 2008; 68: 9194-9201
51. Ng IO, Lai EC, Ho JC, Cheung LK, Ng MM, So MK. Flow cytometric analysis of DNA ploidy in hepatocellular carcinoma. Am J Clin Pathol 1994; 102: 80-86
52. Huang R, Xing Z, Luan Z, Wu T, Wu X, Hu G. A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas. Cancer Res 2003; 63: 3775-3782
53. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST. Identification of liver-intestine cadherin in hepatocellular carcinoma--a potential disease marker. Biochem Biophys Res Commun 2003; 311: 618-624
54. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009; 50: 1453-1463
55. Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, Fan ST. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 2005; 11: 483-489
56. Wang XQ, Luk JM, Garcia-Barcelo M, Miao X, Leung PP, Ho DW, Cheung ST, Lam BY, Cheung CK, Wong AS, Lau SS, So MT, Yu WC, Cai Q, Liu KS, Hui CK, Lau GK, Poon RT, Wong J, Fan ST. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 5248-5252
57. White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216: 1-14
58. Srebrow A, Blaustein M, Kornblihtt AR. Regulation of fibronectin alternative splicing by a basement membrane-like extracellular matrix. FEBS Lett 2002; 514: 285-289
59. Blaustein M, Pelisch F, Coso OA, Bissell MJ, Kornblihtt AR, Srebrow A. Mammary epithelial-mesenchymal interaction regulates fibronectin alternative splicing via phosphatidylinositol 3-kinase. J Biol Chem 2004; 279: 21029-21037
60. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127: 2037-2048
61. Odenthal M, Neubauer K, Meyer zum Büschenfelde KH, Ramadori G. Localization and mRNA steady-state level of cellular fibronectin in rat liver undergoing a CCl4-induced acute damage or fibrosis. Biochim Biophys Acta 1993; 1181: 266-272
62. Chang ML, Chen JC, Alonso CR, Kornblihtt AR, Bissell DM. Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver. Proc Natl Acad Sci USA 2004; 101: 18093-18098
63. Du K, Peng Y, Greenbaum LE, Haber BA, Taub R. HRS/ SRp40-mediated inclusion of the fibronectin EIIIB exon, a possible cause of increased EIIIB expression in proliferating liver. Mol Cell Biol 1997; 17: 4096-4104
64. Matsui S, Takahashi T, Oyanagi Y, Takahashi S, Boku S, Takahashi K, Furukawa K, Arai F, Asakura H. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma. J Hepatol 1997; 27: 843-853
65. Oyama F, Hirohashi S, Sakamoto M, Titani K, Sekiguchi K. Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors. Cancer Res 1993; 53: 2005-2011
66. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12: 1-7
67. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12: 3730-3739
68. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46: 645-654
69. Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 2007; 27: 174-185
70. Oswald C, Stiewe T. In good times and bad: p73 in cancer. Cell Cycle 2008; 7: 1726-1731
71. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-1577
72. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62: 3598-3602
73. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10: 626-633
74. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001; 20: 514-522
75. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23: 5540-5555
76. Tannapfel A, John K, Mise N, Schmidt A, Buhlmann S, Ibrahim SM, Pützer BM. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008; 29: 211-218
77. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009; 1155: 206-221
78. Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 2008; 48: 1251-1261
79. Berasain C, Castillo J, Perugorría MJ, Prieto J, Avila MA. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett 2007; 254: 30-41
80. Alberstein M, Amit M, Vaknin K, O'Donnell A, Farhy C, Lerenthal Y, Shomron N, Shaham O, Sharrocks AD, Ashery-Padan R, Ast G. Regulation of transcription of the RNA splicing factor hSlu7 by Elk-1 and Sp1 affects alternative splicing. RNA 2007; 13: 1988-1999
81. Karni R, Hippo Y, Lowe SW, Krainer AR. The splicingfactor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci USA 2008; 105: 15323-15327
82. Ding WQ, Kuntz SM, Miller LJ. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. Cancer Res 2002; 62: 947-952
83. Pacheco TR, Moita LF, Gomes AQ, Hacohen N, Carmo-Fonseca M. RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts. Mol Biol Cell 2006; 17: 4187-4199
84. Sumanasekera C, Watt DS, Stamm S. Substances that can change alternative splice-site selection. Biochem Soc Trans 2008; 36: 483-490
85. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009; 100: 228-232
86. Du L, Gatti RA. Progress toward therapy with antisensemediated splicing modulation. Curr Opin Mol Ther 2009; 11: 116-123
87. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of premRNA. Nat Chem Biol 2007; 3: 576-583
88. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3: 570-575
89. Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, Tazi J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 2001; 61: 6876-6884
90. Hagiwara M. Alternative splicing: a new drug target of the post-genome era. Biochim Biophys Acta 2005; 1754: 324-331
91. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67: 2072-2080
92. Massiello A, Salas A, Pinkerman RL, Roddy P, Roesser JR, Chalfant CE. Identification of two RNA cis-elements that function to regulate the 5' splice site selection of Bcl-x pre-mRNA in response to ceramide. J Biol Chem 2004; 279: 15799-15804
93. Yang H, Sadda MR, Li M, Zeng Y, Chen L, Bae W, Ou X, Runnegar MT, Mato JM, Lu SC. S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl-x(S). Hepatology 2004; 40: 221-231
94. Ansorena E, García-Trevijano ER, Martínez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC, Avila MA. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 2002; 35: 274-280
95. Ansorena E, Berasain C, López Zabalza MJ, Avila MA, García-Trevijano ER, Iraburu MJ. Differential regulation of the JNK/AP-1 pathway by S-adenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1186-G1193
96. Geib T, Hertel KJ. Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs. PLoS One 2009; 4: e8204
97. Bruno IG, Jin W, Cote GJ. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 2004; 13: 2409-2420
98. Lundin KE, Good L, Strömberg R, Gräslund A, Smith CI. Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet 2006; 56: 1-51
99. Wilusz JE, Devanney SC, Caputi M. Chimeric peptide nucleic acid compounds modulate splicing of the bcl-x gene in vitro and in vivo. Nucleic Acids Res 2005; 33: 6547-6554
100. Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res 2003; 31: 953-962
101. Graziewicz MA, Tarrant TK, Buckley B, Roberts J, Fulton L, Hansen H, Ørum H, Kole R, Sazani P. An endogenous TNFalpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther 2008; 16: 1316-1322
102. Emmrich S, Wang W, John K, Li W, Pützer BM. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 2009; 8: 61
103. Khoo B, Krainer AR. Splicing therapeutics in SMN2 and APOB. Curr Opin Mol Ther 2009; 11: 108-115
104. Alló M, Buggiano V, Fededa JP, Petrillo E, Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, Klinck R, Chabot B, Kornblihtt AR. Control of alternative splicing through siRNA- mediated transcriptional gene silencing. Nat Struct Mol Biol 2009; 16: 717-724
105. Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55: 61-95
106. Hallegger M, Llorian M, Smith CW. Alternative splicing: global insights. FEBS J 2010; 277: 856-866
107. Zhou W, Calciano MA, Jordan H, Brenner M, Johnson S, Wu D, Lei L, Pallares D, Beurdeley P, Rouet F, Gill PS, Bracco L, Soucaille C, Einstein R. High resolution analysis of the human transcriptome: detection of extensive alternative splicing independent of transcriptional activity. BMC Genet 2009; 10: 63